Marketing Applications
How we help with Marketing Applications
Bringing your innovations to improve human health is a complex journey. Our services provide a strategic roadmap for a range of application types, ensuring projects are anchored in a clear pathway to market success. Halloran’s regulatory team can see programs through to marketing applications (NDAs, BLAs, PMAs, 510(k)s) and beyond. We advise our clients on critical late-stage development programs to ensure success. We can act as advisors, authors, and everything in between.
Our services encompass a diverse range of application types, each designed to provide you with a clear path to market authorization:
- 510(k) Application: We guide you through the 510(k) application process for medical devices, facilitating market access while meeting regulatory standards.
- BLA (Biologics License Application): We assist in preparing and submitting BLAs for biopharmaceutical products, ensuring compliance with regulatory requirements for market authorization.
- MAA (Marketing Authorization Application): Our experts help you prepare MAA submissions for European Medicines Agency (EMA) approval, facilitating market entry in the European Union.
- NDA (New Drug Application): Our services include NDA preparation and submission, ensuring your new drug meets regulatory standards for market authorization.
- PMA (Pre-Market Approval): We guide you through the PMA process for medical devices, ensuring compliance with FDA requirements for market entry.
With our expertise spanning these diverse application types, we provide the strategic guidance, preparation, submission, and follow-up support needed to ensure a smooth market entry for your life science innovations.
RELATED INSIGHTS
-
Raw Material Control for Biotechs (Part 2): Clinical Development Considerations
Introduction This is part two of the Halloran Insights article on raw material control. Raw Material Control for Biotechs Part one addressed the importance of establishing a level of raw material control at the earliest stages of product development. This article will focus on maturing the raw material control strategy in preparation for a commercial […]
-
Moving from Discovery to Commercialization in Precision Medicine
The revolution in precision medicine, a form of medicine using information about a person’s own genes or proteins to prevent, diagnose, or treat disease, has reached an exciting phase with the advancement of cell and gene therapies (CGTs). Precision medicine, also known as personalized medicine, is an approach to patient care that enables treatments most […]
-
Rare But Not Forgotten: Opportunities in Rare Disease Drug Development
This article was co-written by Samantha Zappia, Principal Consultant, SK Regulatory Solutions. The World Orphan Drug Congress (WODC) brings together industry leaders working to advance orphan and rare disease drug development in one place for a unique three-day event. Many attendees arrive with the goal of meeting other players in the industry, learning from successes […]
